Return to content in this issue

Hypersensitivity to the CGRP Inhibitor Monoclonal Antibodies Galcanezumab, Erenumab, and Fremanezumab With Tolerance to Eptinezumab

Barroso B^1,2, Rodrigo-Muñoz JM^2,3, Gil-Martínez M^2,3, del Pozo V^2,3, Rodríguez-Vico J⁴, Betancor D^1,2, Valverde-Monge M^1,2, Gómez-López A¹, Sastre J<sup>1,2

1</sup>Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
²CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
³Immunology Department, IIS-Fundación Jiménez Díaz-UAM, Madrid, Spain
⁴Headache Unit, Neurology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

J Investig Allergol Clin Immunol 2024; Vol 34(5) : 348-349
doi: 10.18176/jiaci.1000

• Abstract
• Supplemental Materials

Key words: Galcanezumab, Erenumab, Fremanezumab, Eptinezumab, Hypersensitivity

	Title	Type	Size
	doi10.18176_jiaci.1000_supplemental-materials_1.pdf	pdf	116.82 Kb